AbbVie’s proposed acquisition of ImmunoGen is expected to accelerate AbbVie’s entry into the commercial market for ovarian cancer and includes ImmunoGen’s flagship cancer therapy, ELAHERE (mirvetuximab soravtansine-gynx).
Copyright © 2024 | WordPress Theme by MH Themes